

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128794 A1

(51) International Patent Classification:

A61K 38/00 (2006.01) C07K 14/00 (2006.01)
A61K 38/22 (2006.01) C07K 14/575 (2006.01)

(21) International Application Number:

PCT/US2024/059724

(22) International Filing Date:

12 December 2024 (12.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/610,462 15 December 2023 (15.12.2023) US
63/697,944 23 September 2024 (23.09.2024) US

(71) Applicant: NEUROCRINE BIOSCIENCES, INC.

[US/US]; 6027 Edgewood Bend Court, San Diego, CA 92130 (US).

(72) Inventors: MEZO, Adam, R.; 6027 Edgewood Bend

Court, San Diego, CA 92130 (US). BEHAN, Dominic, P.; 15581 Pinehurst Place, San Diego, CA 92131 (US).
ERCHEGYI, Judit; 4046 Moratalla Terrace, San Diego,

CA 92130 (US). MILLER, Charleen, L.; 1941 Sorrentino Drive, Escondido, CA 92025 (US). RABINOVICH, Aleksandr; 8234 Caminito Maritimo, La Jolla, CA 92037 (US).
SUZARA, Vincent; 1135 Torrey Pines Road, La Jolla, CA 92037 (US).

(74) Agent: MARTINEK, Sebastian et al.; Jones Day, 250 Vesey Street, New York, NY 10281-1047 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV,

(54) Title: FATTY ACID CONJUGATED CYCLIC PEPTIDES




FIG. 1

(57) Abstract: This disclosure provides fatty acid conjugated cyclic peptides, pharmaceutical compositions comprising such fatty acid conjugated cyclic peptides and methods of using such fatty acid conjugated cyclic peptides to treat or prevent diseases associated with the abnormal or dysregulated activity of corticotropin releasing factor (CRT) signaling.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*